Drug Profile
Research programme: neurological disorder therapeutics - ArmaGen Technologies/Janssen
Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator ArmaGen Technologies
- Developer ArmaGen Technologies; Janssen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for research development in Neurological-disorders in USA
- 21 Oct 2020 Early research is ongoing for Neurological disorders in USA (ArmaGen Technologies pipeline, October 2020)
- 28 Aug 2020 No recent reports of development identified for research development in Neurological-disorders in USA